Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Phase II Trial of Exemestane With and Without Bicalutamide as Second Line Therapy After Failure of Androgen Suppression in Advanced Prostate Cancer

NCT00031889 is registered in ClinicalTrials.gov with Swiss Cancer Institute as lead sponsor.

NCT NCT00031889
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00031889 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Phase II Trial of Exemestane With and Without Bicalutamide as Second Line Therapy After Failure of Androgen Suppression in Advanced Prostate Cancer
Lead sponsor
Swiss Cancer Institute
Phase
Phase 2
Overall status
Completed
Start date
August 31, 2001
Completion date
June 30, 2002
Enrollment
5 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer